John H. Kehne - Publications

Neurogen, Beverly Hills, CA, United States 
CRF, GABA, psychopharmacology

67 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any innacuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2013 Ashby CR, Kehne JH, Bartoszyk GD, Renda MJ, Athanasiou M, Pierz KA, Seyfried CA. Electrophysiological evidence for rapid 5-HT₁A autoreceptor inhibition by vilazodone, a 5-HT₁A receptor partial agonist and 5-HT reuptake inhibitor. European Journal of Pharmacology. 714: 359-65. PMID 23872377 DOI: 10.1016/j.ejphar.2013.07.014  1
2013 Avram MJ, Spyker DA, Kehne JH, Cassella JV. The Pharmacokinetics and Pharmacodynamics of Zaleplon Delivered as a Thermally Generated Aerosol in a Single Breath to Volunteers. Journal of Clinical Pharmacology. PMID 23504855 DOI: 10.1177/0091270011436886  0.8
2013 Avram MJ, Spyker DA, Kehne JH, Cassella JV. The pharmacokinetics and pharmacodynamics of zaleplon delivered as a thermally generated aerosol in a single breath to volunteers. Journal of Clinical Pharmacology. 53: 140-50. PMID 23436259 DOI: 10.1177/0091270012436886  1
2012 Cain CK, Maynard GD, Kehne JH. Targeting memory processes with drugs to prevent or cure PTSD. Expert Opinion On Investigational Drugs. 21: 1323-50. PMID 22834476 DOI: 10.1517/13543784.2012.704020  1
2012 Kwentus J, Riesenberg RA, Marandi M, Manning RA, Allen MH, Fishman RS, Spyker DA, Kehne JH, Cassella JV. Rapid acute treatment of agitation in patients with bipolar I disorder: a multicenter, randomized, placebo-controlled clinical trial with inhaled loxapine. Bipolar Disorders. 14: 31-40. PMID 22329470 DOI: 10.1111/j.1399-5618.2011.00975.x  1
2012 Palfreyman MG, Kehne JH. Does 5-HT have a role in anxiety and the action of anxiolytics? 5-Hydroxytryptamine in Psychiatry: a Spectrum of Ideas. DOI: 10.1093/acprof:oso/9780192620118.003.0017  1
2012 Kehne JH, Maynard GD. GABA and Schizophrenia Targets and Emerging Therapies For Schizophrenia. 425-467. DOI: 10.1002/9781118309421.ch15  1
2011 Hodgetts KJ, Ge P, Yoon T, De Lombaert S, Brodbeck R, Gulianello M, Kieltyka A, Horvath RF, Kehne JH, Krause JE, Maynard GD, Hoffman D, Lee Y, Fung L, Doller D. Discovery of N-(1-ethylpropyl)-[3-methoxy-5-(2-methoxy-4-trifluoromethoxyphenyl)-6-methyl-pyrazin-2-yl]amine 59 (NGD 98-2): an orally active corticotropin releasing factor-1 (CRF-1) receptor antagonist. Journal of Medicinal Chemistry. 54: 4187-206. PMID 21618986 DOI: 10.1021/jm200365y  1
2011 Lesem MD, Tran-Johnson TK, Riesenberg RA, Feifel D, Allen MH, Fishman R, Spyker DA, Kehne JH, Cassella JV. Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapine. The British Journal of Psychiatry : the Journal of Mental Science. 198: 51-8. PMID 21200077 DOI: 10.1192/bjp.bp.110.081513  1
2011 Rowlett JK, Kehne JH, Sprenger KJ, Maynard GD. Emergence of anti-conflict effects of zolpidem in rhesus monkeys following extended post-injection intervals. Psychopharmacology. 214: 855-62. PMID 21103864 DOI: 10.1007/s00213-010-2093-3  1
2010 Kehne JH, Cain CK. Therapeutic utility of non-peptidic CRF1 receptor antagonists in anxiety, depression, and stress-related disorders: evidence from animal models. Pharmacology & Therapeutics. 128: 460-87. PMID 20826181 DOI: 10.1016/j.pharmthera.2010.08.011  1
2010 Jackson MJ, Andree TH, Hansard M, Hoffman DC, Hurtt MR, Kehne JH, Pitler TA, Smith LA, Stack G, Jenner P. The dopamine D(2) receptor partial agonist aplindore improves motor deficits in MPTP-treated common marmosets alone and combined with L-dopa. Journal of Neural Transmission (Vienna, Austria : 1996). 117: 55-67. PMID 19809864 DOI: 10.1007/s00702-009-0323-9  1
2010 Morgan PT, Kehne JH, Sprenger KJ, Malison RT. Retrograde effects of triazolam and zolpidem on sleep-dependent motor learning in humans. Journal of Sleep Research. 19: 157-64. PMID 19682231 DOI: 10.1111/j.1365-2869.2009.00757.x  1
2008 Kehne JH, Andree TH, Heinrich JN. D2 receptor partial agonists: treatment of CNS disorders of dopamine function. Current Topics in Medicinal Chemistry. 8: 1068-88. PMID 18691133 DOI: 10.2174/156802608785161394  1
2008 Kehne JH, Maynard GD. CRF1 receptor antagonists: treatment of stress-related disorders Drug Discovery Today: Therapeutic Strategies. 5: 161-168. DOI: 10.1016/j.ddstr.2008.09.003  1
2007 Kehne JH. The CRF1 receptor, a novel target for the treatment of depression, anxiety, and stress-related disorders. Cns & Neurological Disorders Drug Targets. 6: 163-82. PMID 17511614 DOI: 10.2174/187152707780619344  1
2007 Duman RS, Kehne JH. Depression. Cns & Neurological Disorders Drug Targets. 6: 161-2. PMID 17511613 DOI: 10.2174/187152707780619317  1
2007 Duman RS, Kehne JH. Depression. Cns & Neurological Disorders Drug Targets. 6: 85-6. PMID 17430146 DOI: 10.2174/187152707780363249  1
2003 Kehne JH, Maynard GD, De Lombaert S, Krause JE. Chapter 2. Neuropeptide receptor antagonists for CNS disorders Annual Reports in Medicinal Chemistry. 38: 11-20.  1
2000 Kehne JH, Coverdale S, McCloskey TC, Hoffman DC, Cassella JV. Effects of the CRF(1) receptor antagonist, CP 154,526, in the separation-induced vocalization anxiolytic test in rat pups. Neuropharmacology. 39: 1357-67. PMID 10818252 DOI: 10.1016/S0028-3908(00)00043-5  1
1998 Tsibulsky VL, Grocki S, Dashevsky BA, Kehne JH, Schmidt CJ, Sorensen SM, Frank RA. Mixed D2/5-HT2A antagonism of cocaine-induced facilitation of brain stimulation reward. Pharmacology, Biochemistry, and Behavior. 59: 275-80. PMID 9476970 DOI: 10.1016/S0091-3057(97)00445-0  1
1997 Feldman DJ, Frank RA, Kehne JH, Flannery R, Brown D, Soni S, Byrd G, Shah S. Mixed D2/5-HT2 antagonism differentially affects apomorphine- and amphetamine-induced stereotyped behavior. Pharmacology, Biochemistry, and Behavior. 58: 565-72. PMID 9300620 DOI: 10.1016/S0091-3057(97)00292-X  1
1997 Kudlacz EM, Knippenberg RW, Shatzer SA, Kehne JH, McCloskey TC, Burkholder TP. The peripheral NK-1/NK-2 receptor antagonist MDL 105,172A inhibits tachykinin-mediated respiratory effects in guinea-pigs. Journal of Autonomic Pharmacology. 17: 109-19. PMID 9234081  1
1997 Kehne JH, Kane JM, Chaney SF, Hurst G, McCloskey TC, Petty MA, Senyah Y, Wolf HH, Zobrist R, White HS. Preclinical characterization of MDL 27,192 as a potential broad spectrum anticonvulsant agent with neuroprotective properties. Epilepsy Research. 27: 41-54. PMID 9169290 DOI: 10.1016/S0920-1211(96)01020-0  1
1997 Baron BM, Harrison BL, Kehne JH, Schmidt CJ, van Giersbergen PL, White HS, Siegel BW, Senyah Y, McCloskey TC, Fadayel GM, Taylor VL, Murawsky MK, Nyce P, Salituro FG. Pharmacological characterization of MDL 105,519, an NMDA receptor glycine site antagonist. European Journal of Pharmacology. 323: 181-92. PMID 9128837 DOI: 10.1016/S0014-2999(97)00045-9  1
1997 Schmidt CJ, Kehne JH, Carr AA. MDL 100,907: A selective 5-HT(2A) receptor antagonist for the treatment of schizophrenia Cns Drug Reviews. 3: 49-67. DOI: 10.1111/j.1527-3458.1997.tb00316.x  1
1996 Thomas CE, Bernardelli P, Bowen SM, Chaney SF, Friedrich D, Janowick DA, Jones BK, Keeley FJ, Kehne JH, Ketteler B, Ohlweiler DF, Paquette LA, Robke DJ, Fevig TL. Cyclic nitrone free radical traps: isolation, identification, and synthesis of 3,3-dimethyl-3,4-dihydroisoquinolin-4-ol N-oxide, a metabolite with reduced side effects. Journal of Medicinal Chemistry. 39: 4997-5004. PMID 8960560 DOI: 10.1021/jm960244n  1
1996 Padich RA, McCloskey TC, Kehne JH. 5-HT modulation of auditory and visual sensorimotor gating: II. Effects of the 5-HT2A antagonist MDL 100,907 on disruption of sound and light prepulse inhibition produced by 5-HT agonists in Wistar rats. Psychopharmacology. 124: 107-16. PMID 8935805  1
1996 Kehne JH, Padich RA, McCloskey TC, Taylor VL, Schmidt CJ. 5-HT modulation of auditory and visual sensorimotor gating: I. Effects of 5-HT releasers on sound and light prepulse inhibition in Wistar rats. Psychopharmacology. 124: 95-106. PMID 8935804 DOI: 10.1007/BF02245609  1
1996 Kehne JH, Ketteler HJ, McCloskey TC, Sullivan CK, Dudley MW, Schmidt CJ. Effects of the selective 5-HT2A receptor antagonist MDL 100,907 on MDMA-induced locomotor stimulation in rats. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 15: 116-24. PMID 8840347 DOI: 10.1016/0893-133X(95)00160-F  1
1996 Moser PC, Moran PM, Frank RA, Kehne JH. Reversal of amphetamine-induced behaviours by MDL 100,907, a selective 5-HT2A antagonist. Behavioural Brain Research. 73: 163-7. PMID 8788496 DOI: 10.1016/0166-4328(96)00090-3  1
1996 Kehne JH, Baron BM, Carr AA, Chaney SF, Elands J, Feldman DJ, Frank RA, van Giersbergen PL, McCloskey TC, Johnson MP, McCarty DR, Poirot M, Senyah Y, Siegel BW, Widmaier C. Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile. The Journal of Pharmacology and Experimental Therapeutics. 277: 968-81. PMID 8627580  1
1995 Frank RA, Tsibulsky V, Grocki S, Dashevsky B, Kehne JH, Schmidt CJ, Sorensen SM. Mixed D2/5-HT2A antagonism of amphetamine-induced facilitation of brain stimulation reward. Pharmacology, Biochemistry, and Behavior. 52: 799-804. PMID 8587922 DOI: 10.1016/0091-3057(95)00184-X  1
1995 Kehne JH, Baron BM, Harrison BL, McCloskey TC, Palfreyman MG, Poirot M, Salituro FG, Siegel BW, Slone AL, Van Giersbergen PL. MDL 100,458 and MDL 102,288: two potent and selective glycine receptor antagonists with different functional profiles. European Journal of Pharmacology. 284: 109-18. PMID 8549613 DOI: 10.1016/0014-2999(95)00375-U  1
1994 Kane JM, Staeger MA, Dalton CR, Miller FP, Dudley MW, Ogden AM, Kehne JH, Ketteler HJ, McCloskey TC, Senyah Y. 5-Aryl-3-(alkylthio)-4H-1,2,4-triazoles as selective antagonists of strychnine-induced convulsions and potential antispastic agents. Journal of Medicinal Chemistry. 37: 125-32. PMID 8289185  1
1993 Sorensen SM, Kehne JH, Fadayel GM, Humphreys TM, Ketteler HJ, Sullivan CK, Taylor VL, Schmidt CJ. Characterization of the 5-HT2 receptor antagonist MDL 100907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies. The Journal of Pharmacology and Experimental Therapeutics. 266: 684-91. PMID 8102646  1
1993 Schmidt CJ, Kehne JH, Carr AA, Fadayel GM, Humphreys TM, Kettler HJ, McCloskey TC, Padich RA, Taylor VL, Sorensen SM. Contribution of serotonin neurotoxins to understanding psychiatric disorders: the role of 5-HT2 receptors in schizophrenia and antipsychotic activity. International Clinical Psychopharmacology. 8: 25-32. PMID 7911139  1
1993 Palfreyman MG, Schmidt CJ, Sorensen SM, Dudley MW, Kehne JH, Moser P, Gittos MW, Carr AA. Electrophysiological, biochemical and behavioral evidence for 5-HT2 and 5-HT3 mediated control of dopaminergic function. Psychopharmacology. 112: S60-7. PMID 7831442 DOI: 10.1007/BF02245008  1
1992 Kehne JH, McCloskey TC, Taylor VL, Black CK, Fadayel GM, Schmidt CJ. Effects of the serotonin releasers 3,4-methylenedioxymethamphetamine (MDMA), 4-chloroamphetamine (PCA) and fenfluramine on acoustic and tactile startle reflexes in rats. The Journal of Pharmacology and Experimental Therapeutics. 260: 78-89. PMID 1731054  1
1992 Salituro FG, Harrison BL, Baron BM, Nyce PL, Stewart KT, Kehne JH, White HS, McDonald IA. 3-(2-Carboxyindol-3-yl)propionic acid-based antagonists of the N-methyl-D-aspartic acid receptor associated glycine binding site. Journal of Medicinal Chemistry. 35: 1791-9. PMID 1534125  1
1992 Kane JM, Huber EW, Miller FP, Kehne JH. Synthesis and pharmacology of 3-aryl-5,6-dihydro-6-oxo-1(4H)-pyridazineacetic acid derivatives. Die Pharmazie. 47: 249-51. PMID 1518880  1
1992 Kehne JH, Ketteler HJ, Kane JM, McCloskey TC, Senyah Y, Palfreyman MG. MDL 27,531 reduces spontaneous hindlimb contractions in rats with chronic transections of the spinal cord. Neuroscience Letters. 147: 101-5. PMID 1480315 DOI: 10.1016/0304-3940(92)90784-5  1
1992 Miller JA, Dudley MW, Kehne JH, Sorensen SM, Kane JM. MDL 26,479: a potential cognition enhancer with benzodiazepine inverse agonist-like properties. British Journal of Pharmacology. 107: 78-86. PMID 1330168  1
1992 Kehne JH, Kane JM, Miller FP, Ketteler HJ, Braun DL, Senyah Y, Chaney SF, Abdallah A, Dudley MW, Ogden AM. MDL 27,531 selectively reverses strychnine-induced seizures in mice. British Journal of Pharmacology. 106: 910-6. PMID 1327393  1
1992 Miller JA, Dudley MW, Kehne JH, Sorensen SM, Wenstrup DL, Kane JM. MDL 26,479. Cognition enhancer Drugs of the Future. 17: 21-23.  1
1991 Kehne JH, McCloskey TC, Baron BM, Chi EM, Harrison BL, Whitten JP, Palfreyman MG. NMDA receptor complex antagonists have potential anxiolytic effects as measured with separation-induced ultrasonic vocalizations. European Journal of Pharmacology. 193: 283-92. PMID 1675993 DOI: 10.1016/0014-2999(91)90141-C  1
1991 Kehne JH, Boulis NM, Davis M. Effects of the phosphodiesterase inhibitor rolipram on the acoustic startle response in rats. Psychopharmacology. 105: 27-36. PMID 1660609 DOI: 10.1007/BF02316860  1
1991 Sorensen SM, Kane JM, Miller JA, Moser P, Dudley MW, Kehne JH, Palfreyman MG. A novel triazole with cognition-enhancing potential Drug News and Perspectives. 4: 624-627.  1
1990 Schmidt CJ, Kehne JH. Neurotoxicity of MDMA: neurochemical effects. Annals of the New York Academy of Sciences. 600: 665-80; discussion 6. PMID 1979217  1
1990 Boulis NM, Kehne JH, Miserendino MJ, Davis M. Differential blockade of early and late components of acoustic startle following intrathecal infusion of 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) or D,L-2-amino-5-phosphonovaleric acid (AP-5). Brain Research. 520: 240-6. PMID 1976408 DOI: 10.1016/0006-8993(90)91711-O  1
1989 Davis M, Commissaris RL, Yang S, Wagner KR, Kehne JH, Cassella JV, Boulis NM. Spinal vs. supraspinal sites of action of the alpha 2-adrenergic agonists clonidine and ST-91 on the acoustic startle reflex. Pharmacology, Biochemistry, and Behavior. 33: 233-40. PMID 2571168 DOI: 10.1016/0091-3057(89)90455-3  1
1988 Kehne JH, Cassella JV, Davis M. Anxiolytic effects of buspirone and gepirone in the fear-potentiated startle paradigm. Psychopharmacology. 94: 8-13. PMID 2894703 DOI: 10.1007/BF00735872  1
1988 Davis M, Cassella JV, Kehne JH. Serotonin does not mediate anxiolytic effects of buspirone in the fear-potentiated startle paradigm: comparison with 8-OH-DPAT and ipsapirone. Psychopharmacology. 94: 14-20. PMID 2894698 DOI: 10.1007/BF00735873  1
1987 Kehne JH, Cassella JV, Aghajanian GK, Tallman JF, Davis M. Pertussis toxin or 8-bromo-cAMP block inhibition of the acoustic startle response by the alpha 2-adrenergic agonist ST-91. Brain Research. 406: 87-92. PMID 3032362 DOI: 10.1016/0006-8993(87)90771-2  1
1986 Davis M, Cassella JV, Wrean WH, Kehne JH. Serotonin receptor subtype agonists: differential effects on sensorimotor reactivity measured with acoustic startle. Psychopharmacology Bulletin. 22: 837-43. PMID 3025912  1
1986 Kehne JH, Astrachan DI, Astrachan E, Tallman JF, Davis M. The role of spinal cord cyclic AMP in the acoustic startle response in rats. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 6: 3250-7. PMID 3021926  1
1985 Kehne JH, Davis M. Central noradrenergic involvement in yohimbine excitation of acoustic startle: effects of DSP4 and 6-OHDA. Brain Research. 330: 31-41. PMID 3921192 DOI: 10.1016/0006-8993(85)90005-8  1
1985 Kehne JH, Gallager DW, Davis M. Spinalization unmasks clonidine's alpha 1-adrenergic mediated excitation of the flexor reflex in rats. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 5: 1583-90. PMID 2861260  1
1985 Davis M, Kehne JH, Commissaris RL. Antagonism of apomorphine-enhanced startle by alpha 1-adrenergic antagonists. European Journal of Pharmacology. 108: 233-41. PMID 2859209 DOI: 10.1016/0014-2999(85)90445-5  1
1984 Kehne JH, Davis M. Strychnine increases acoustic startle amplitude but does not alter short-term or long-term habituation. Behavioral Neuroscience. 98: 955-68. PMID 6095880 DOI: 10.1037//0735-7044.98.6.955  1
1983 Marwaha J, Kehne JH, Commissaris RL, Lakoski J, Shaw W, Davis M. Spinal clonidine inhibits neural firing in locus coeruleus. Brain Research. 276: 379-83. PMID 6414650 DOI: 10.1016/0006-8993(83)90752-7  1
1983 Gallager DW, Kehne JH, Wakeman EA, Davis M. Development changes in pharmacological responsivity of the acoustic startle reflex: effects of picrotoxin. Psychopharmacology. 79: 87-93. PMID 6405442 DOI: 10.1007/BF00427790  1
1983 Menkes DB, Kehne JH, Gallager DW, Aghajanian GK, Davis M. Functional supersensitivity of CNS alpha 1-adrenoceptors following chronic antidepressant treatment. Life Sciences. 33: 181-8. PMID 6306376 DOI: 10.1016/0024-3205(83)90411-3  1
1982 Davis M, Parisi T, Gendelman DS, Tischler M, Kehne JH. Habituation and sensitization of startle reflexes elicited electrically from the brainstem. Science (New York, N.Y.). 218: 688-90. PMID 7134967 DOI: 10.1126/science.7134967  1
1981 Kehne JH, Gallager DW, Davis M. Strychnine: brainstem and spinal mediation of excitatory effects on acoustic startle. European Journal of Pharmacology. 76: 177-86. PMID 7333355 DOI: 10.1016/0014-2999(81)90499-4  1
1981 Kehne JH, Sant WW, Sorenson CA. The effects of radio-frequency lesions of the nucleus accumbens on d-amphetamine-induced locomotor and rearing behavior in rats. Psychopharmacology. 75: 363-7. PMID 6803281  1
1978 Kehne JH, Sorenson CA. The effects of pimozide and phenoxybenzamine pretreatments on amphetamine and apomorphine potentiation of the acoustic startle response in rats. Psychopharmacology. 58: 137-44. PMID 98780 DOI: 10.1007/BF00426896  1
Show low-probability matches.